2022
Non-alcoholic fatty liver disease (NAFLD): a significant predictor of gestational diabetes mellitus (GDM) and early pregnancy miscarriages—prospective study in Rajarata Pregnancy Cohort (RaPCo)
Koralegedara IS, Warnasekara JN, Dayaratne KG, De Silva FN, Premadasa JK, Agampodi SB. Non-alcoholic fatty liver disease (NAFLD): a significant predictor of gestational diabetes mellitus (GDM) and early pregnancy miscarriages—prospective study in Rajarata Pregnancy Cohort (RaPCo). BMJ Open Gastroenterology 2022, 9: e000831. PMID: 35193889, PMCID: PMC8867246, DOI: 10.1136/bmjgast-2021-000831.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseGestational diabetes mellitusEarly pregnancy miscarriageFatty liver diseasePregnancy miscarriageRisk factorsDiabetes mellitusLiver diseasePregnant womenRelative riskEffect of NAFLDImpact of NAFLDPopulation-based prospective cohort studyRepeat oral glucose tolerance testFirst trimester pregnant womenOral glucose tolerance testPregnancy care programsProspective cohort studyOnly independent predictorBody mass indexGlucose tolerance testWeeks of gestationSignificant risk factorsMajor risk factorHigh-risk mothersImpact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam VC, Bettinger D, Thimme R, Taddei TH, Kaplan DE, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances In Gastroenterology 2022, 15: 17562848221100106. PMID: 36199289, PMCID: PMC9527996, DOI: 10.1177/17562848221100106.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseImpact of NAFLDBody mass indexOverall survivalHepatocellular carcinomaLiver diseasePresence of NAFLDMultivariable Cox proportional hazardsMedian body mass indexAdvanced-stage hepatocellular carcinomaGrade 2 hypertensionLower starting doseInternational cohort studySimilar clinical benefitsFatty liver diseaseStage hepatocellular carcinomaCox proportional hazardsLogistic regression modellingStarting doseAdverse eventsCohort studyPrognostic factorsClinical outcomesMass indexClinical benefit
2021
Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.
Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam V, Bettinger D, Thimme R, Taddei T, Kaplan D, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study. Journal Of Clinical Oncology 2021, 39: 289-289. DOI: 10.1200/jco.2021.39.3_suppl.289.Peer-Reviewed Original ResearchImpact of NAFLDOverall survivalHepatocellular carcinomaLiver diseaseNon-alcoholic fatty liver diseaseMultivariable Cox proportional hazardsAdvanced-stage hepatocellular carcinomaLower starting doseSorafenib-related toxicityFatty liver diseaseStage hepatocellular carcinomaCox proportional hazardsLogistic regression modellingStarting doseMedian BMIPrognostic factorsSpecialist centresHCC patientsNAFLDTreatment responseInternational cohortPatientsSorafenibDemographic dataSurvival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply